Clinical development of insulin-like growth factor receptor—1 (IGF-1R) inhibitors: At the crossroad?

Insulin like growth factor receptor (IGF-1R) targeting became one of the most investigated areas in anticancer drug development during the last decade. Strategies aiming to block IGF-1R activity include monoclonal antibodies, tyrosine kinase inhibitors and anti-ligands antibodies. Initial enthusiasm...

Descripción completa

Detalles Bibliográficos
Autores principales: Gombos, Andrea, Metzger-Filho, Otto, Dal Lago, Lissandra, Awada-Hussein, Ahmad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484277/
https://www.ncbi.nlm.nih.gov/pubmed/22415797
http://dx.doi.org/10.1007/s10637-012-9811-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484277/
https://www.ncbi.nlm.nih.gov/pubmed/22415797
http://dx.doi.org/10.1007/s10637-012-9811-0

Ejemplares similares